Related by context. All words. (Click for frequent words.) 65 tumor histology 65 TT genotype 64 poor metabolizers 64 β blockers 63 intact parathyroid hormone 63 urodynamic parameters 63 multivariable analyzes 63 multivariate analyzes 62 GH deficiency 62 periprocedural MI 62 pretransplant 62 CC genotype 62 unfavorable cytogenetics 62 CYP#D# inhibitor 62 tirofiban 62 lowest tertile 62 confidence interval #.#-#.# 62 multivariable adjusted 62 Subgroup analyzes 62 liver histology 62 carotid stenosis 62 CORE OM 61 radiotherapy RT 61 LV dysfunction 61 intravesical therapy 61 T2DM 61 P = .# 61 tipranavir r 61 transrectal ultrasound guided 61 p = .# [002] 61 primary aldosteronism 61 MMSE score 61 elevated LDH 61 de novo AML 61 homozygotes 61 euthyroid 61 attain statistical significance 61 antibiotic prophylaxis 60 perioperatively 60 comorbid disorders 60 colorectal adenoma 60 dose atorvastatin 60 % CI #.#-#.# [007] 60 histological subtype 60 prostate carcinoma 60 clinicopathological 60 paclitaxel eluting stents 60 antibody titer 60 lipid lowering therapy 60 univariate analyzes 60 -#.# ± [002] 60 beta blocker therapy 60 prognostic significance 60 angiographically 60 ASCUS 60 preoperative PSA 60 LV ejection fraction 60 relapsed MM 60 AST ALT 60 carotid IMT 60 creatinine ratio 60 histologically confirmed 60 prostate cancer CaP 60 % CI #.#-#.# [003] 60 noncardiac 60 cranial irradiation 59 oncologic outcomes 59 pretest probability 59 null responder 59 plasma pharmacokinetics 59 methacholine challenge 59 urolithiasis 59 SGPT 59 advanced neoplasia 59 SLNB 59 CI #.#-#.# [002] 59 thiopurine 59 prognostic indicators 59 CI -#.# 59 gene polymorphism 59 hyperacute 59 univariate analysis 59 IPAH 59 TRUS 59 PCa 59 TURBT 59 cytologic 59 confidence intervals CIs 59 serum creatinine levels 59 hematological parameters 59 abnormal cytology 59 nondiabetic patients 59 artery stenosis 59 risk reducing salpingo 59 adrenalectomy 59 clinicopathologic 59 postoperative AF 59 HGPIN 59 clinicopathological features 59 affective psychosis 59 posttransplant 59 ATACAND 59 advanced adenoma 59 hMG 59 histologic subtype 59 MDRD 59 perioperative complications 59 pT3 59 intratympanic 59 concomitant medications 59 T1DM 59 urodynamic 59 radical prostatectomy RP 59 QTc 59 renal artery stenosis 59 ECOG PS 58 WOMAC pain 58 seminal vesicle invasion 58 MADRS score 58 symptomatic VTE 58 CR nPR 58 glycoprotein IIb IIIa inhibitors 58 MetS 58 colorectal liver metastases 58 #OHD 58 % Confidence Interval 58 postintervention 58 acute cholecystitis 58 extracapsular extension 58 serum lipid 58 parous women 58 liposomal amphotericin B 58 adnexal mass 58 HbA 1c levels 58 urine cytology 58 thrombotic complications 58 CYP#D# 58 vesicoureteral reflux 58 transabdominal 58 radical nephrectomy 58 hematopoietic cancers 58 HER2 expression 58 nonischemic 58 ultrasonographic 58 baseline HbA1c 58 postoperative complication 58 thrombophilia 58 BPS IC 58 aortic insufficiency 58 ALT elevations 58 SCr 58 ß blockers 58 endometrial thickness 58 dyslipidaemia 58 paroxysmal AF 58 antiepileptics 58 BRCA2 carriers 58 NIH CPSI 58 p = #.# [003] 58 bronchial hyperresponsiveness 58 neurocognitive function 58 IOP lowering 58 heterozygotes 58 logistic regression model 58 thromboembolic 58 VTE prophylaxis 58 renal cysts 58 posttreatment 58 Symptom severity 58 HIV HCV coinfected 58 angiotensin II receptor blockers 58 clomipramine 58 baseline LDH 58 rheumatoid factor 58 metaplasia 58 neoplasias 58 carotid plaques 58 multivariate Cox 58 tertiles 58 HRQoL 58 methotrexate monotherapy 58 comorbid depression 58 prognostic factors 58 follicular lymphoma FL 57 mucinous 57 monophasic 57 Heavy menstrual bleeding 57 Cypher Stent 57 confidence interval CI 57 polytherapy 57 HIV uninfected 57 nonalcoholic steatohepatitis NASH 57 periprocedural 57 PSA nadir 57 nasal polyposis 57 % CI #.#-#.# [008] 57 platelet reactivity 57 ovarian carcinoma 57 ‰ ¥ 57 ventricular tachyarrhythmia 57 norethindrone acetate 57 thromboembolic disease 57 CIN2 + 57 EGFR mutation status 57 albumin excretion 57 NMIBC 57 aortic regurgitation 57 leiomyomas 57 antiarrhythmic drugs 57 Flu Cy 57 patients undergoing CABG 57 adjuvant therapies 57 multivariate adjustment 57 transferrin saturation 57 amisulpride 57 sonographically guided 57 BMI z 57 Multivariate analysis 57 antiandrogens 57 thrombocytopenic 57 serum concentrations 57 PsA 57 nonobese 57 eosinophil count 57 systolic function 57 adenoma detection 57 isolated systolic hypertension 57 antiplatelet medications 57 serum lipid levels 57 adenomatous 57 hypercalciuria 57 abacavir lamivudine 57 multivariable analysis 57 comorbidity 57 gastric cardia 57 haematologic 57 premenopause 57 comorbid conditions 57 pelvic lymphadenectomy 57 HbA1C levels 57 IGRAs 57 coronary stenosis 57 thyroglobulin 57 psychiatric comorbidity 57 antiphospholipid antibodies 57 HRCT 57 endoscopic ultrasonography 57 comorbid anxiety 57 pCR 57 CsA 57 symptomatology 57 pT2 57 bone scintigraphy 57 certolizumab 57 serum TSH 57 % CI #.#-#.# [006] 57 nondepressed 57 carotid artery stenting CAS 57 thromboprophylaxis 57 T1a 57 nonresponders 57 tertile 57 ABCB1 57 logistic regression models 57 corrected QT interval 57 hemodynamic variables 57 supratentorial 57 recurrent venous thromboembolism 57 sacral neuromodulation 57 electrophysiologic 57 lymphoproliferative disorders 57 microscopic colitis 57 chest radiographs 57 hypertensives 57 left ventricular systolic 57 chronicity 57 NSTE ACS 57 pharmacokinetic parameters 57 TEAEs 57 sonographically 57 OSAHS 57 atherothrombotic 57 androgen suppression 57 neutropaenia 57 BRCA mutation carriers 57 SGRQ 57 SNHL 57 adenoidectomy 57 transurethral resection 57 BRCA2 mutation carriers 57 thyroid carcinoma 57 bronchoalveolar lavage 57 LUTS 57 nephron sparing surgery 57 NIHSS score 57 bivariate analyzes 57 MR spectroscopy 57 flutamide 57 vaginal hysterectomy 57 urothelial carcinoma 57 ECLS 57 interrater reliability 57 EQ 5D 57 subclinical hypothyroidism 57 Stent thrombosis 57 erection hardness 57 LVSD 57 caspofungin 57 CI #.#-#.# [001] 57 mycophenolate 57 carotid plaque 57 serum PSA 57 alanine aminotransferase 57 bladder carcinoma 57 penetrance 57 Hcy 57 lipid lowering drugs 57 CIN3 57 nodal metastases 57 antiarrhythmic drug 57 elevated IOP 57 familial aggregation 57 EBRT 57 psychiatric comorbidities 57 univariate 57 = #.#-#.# 56 osteopenic 56 definite stent thrombosis 56 pharmacologic treatments 56 CVD mortality 56 antiangiogenic therapy 56 μg liter 56 bypass grafting 56 premorbid 56 hypogonadotropic hypogonadism 56 allele frequencies 56 reperfusion therapy 56 POAG 56 collagenous colitis 56 APTIVUS r 56 percutaneous vertebroplasty 56 umol L 56 APOE genotype 56 lumbar spine BMD 56 gm dL 56 oncological outcomes 56 HRQL 56 hsCRP levels 56 resynchronization therapy 56 mycophenolate mofetil MMF 56 carotid revascularization 56 recurrent VTE 56 atopic 56 nicardipine 56 salmeterol fluticasone 56 dosage regimens 56 elevated ALT 56 HLA DR4 56 transvaginal sonography 56 aortic root replacement 56 prostate cancer PCa 56 hypertension diabetes mellitus 56 parenchymal 56 abdominal adiposity 56 albumin excretion rate 56 intravenous thrombolysis 56 μmol L 56 thromboembolic events 56 autologous SCT 56 diabetes mellitus DM 56 nonvertebral fracture 56 reflux esophagitis 56 liver metastasis 56 thromboembolic complications 56 hepatectomy 56 VLBW 56 fasting plasma 56 progression TTP 56 gastroduodenal 56 neoadjuvant 56 hepatorenal syndrome 56 microsatellite instability 56 FDG uptake 56 autonomic dysfunction 56 lipid lowering medications 56 hepatic encephalopathy HE 56 Poisson regression 56 KRAS mutations occur 56 ICD implantation 56 postdischarge 56 epithelial ovarian cancer 56 renal tumors 56 prepubertal 56 mutated K ras 56 lymphadenectomy 56 postexposure prophylaxis 56 TMP SMX 56 polyarticular 56 immunochemical fecal occult 56 sulfasalazine 56 BENICAR HCT 56 conjugated equine estrogen 56 OGTT 56 antioxidant supplementation 56 HoLEP 56 PNH patients 56 serum urate levels 56 Papillary 56 ACEIs 56 seminomas 56 prognostic biomarker 56 systolic hypertension 56 FDA defined valvulopathy 56 TOP2A 56 adverse cytogenetics 56 bivariate analysis 56 nonfatal MI 56 stable angina 56 serum cortisol 56 variance ANOVA 56 Randomized trials 56 dysfunctional voiding 56 GnRH agonists 56 prognostic variables 56 Univariate analysis 56 prevalences 56 adenomatous polyps 56 normotensive 56 postop 56 genotypic resistance 56 lymphocyte count 56 binary restenosis 56 non squamous histology 56 exhaled nitric oxide 56 atopic asthma 56 PSADT 56 hyperoxaluria 56 femoral neck BMD 56 HOMA IR 56 fluvastatin 56 6 mercaptopurine 56 lipid lowering agents 56 serum ALT 56 mL/min/#.# m 2 56 biochemical recurrence 56 subclinical atherosclerosis 56 electrical cardioversion 56 logistic regression analysis 56 preoperatively 56 coronary stenoses 56 abacavir Ziagen 56 MACCE 56 prostatic adenocarcinoma 56 carotid artery stenosis 56 renal biopsy 56 idiopathic myelofibrosis 56 systolic dysfunction 56 hypercoagulable 56 Subgroup analysis 56 logistic regression analyzes 56 adiponectin concentrations 56 preoperative chemotherapy 56 lipid parameters 56 subscore 56 lipid elevations 56 nephrolithiasis 56 perfusion abnormalities 56 postoperative radiotherapy 56 hormone receptor negative 56 cardiac repolarization 56 serum magnesium 56 androgen ablation 56 pharmacodynamic PD 56 postoperative morbidity 56 NNRTI resistance 56 vertebral fracture 56 demyelinating 56 alanine aminotransferase ALT 56 cytoreductive nephrectomy 56 Gram stain 56 locoregional recurrence 56 aortic atherosclerosis 56 depressive symptomatology 56 thyrotropin 56 interpersonal psychotherapy 56 atrioventricular block 56 gene polymorphisms 56 Cognitive impairment 56 virological response 56 NYHA functional class 56 adjuvant cisplatin 56 antiplatelet drugs 56 comorbidities 56 ADAS Cog 56 interobserver 56 papillary thyroid carcinoma 56 SSRI citalopram 56 serum retinol 56 interobserver agreement 56 Ejection Fraction 56 DAS# remission 56 NIHSS 56 hydroxyvitamin D concentrations 55 thyroid nodules 55 angiotensin converting enzyme inhibitors 55 histologic findings 55 sulphonylureas 55 rCBF 55 adenocarcinomas 55 cTnI 55 juvenile idiopathic arthritis 55 Kaplan Meier analysis 55 antibody titers 55 atherosclerotic renal artery stenosis 55 recurrent miscarriage 55 hematologic parameters 55 interobserver reliability 55 histopathological 55 LNG IUS 55 labetalol 55 ANCOVA 55 transesophageal 55 sUA 55 CTEPH 55 ALT elevation 55 #F FDG PET 55 ischemic cardiomyopathy 55 CK MB 55 VUR 55 obstructive coronary artery 55 revascularization procedures 55 symptomatic paroxysmal AF 55 aldosterone antagonist 55 leukocyte count 55 plasma adiponectin 55 intracoronary 55 intima media thickness 55 serum estradiol 55 metabolic parameters 55 somatostatin analog 55 multiple logistic regression 55 histologically proven 55 airway responsiveness 55 glomerular filtration 55 Adjunctive 55 seropositivity 55 adenoma recurrence 55 macroalbuminuria 55 Charlson comorbidity index 55 spirometric 55 atypical hyperplasia 55 p ≤ 55 Type IIa 55 hypogonadal 55 anastomotic leak 55 adenotonsillectomy 55 HSCT 55 arterial thromboembolic events 55 subgroup analyzes 55 plasma folate 55 total thyroidectomy 55 thrombus aspiration 55 pulmonary dysfunction 55 ertapenem 55 sinus node dysfunction 55 antiandrogen 55 psychosocial functioning 55 sd = 55 recurrent GBM 55 seronegative 55 NNT = 55 serum selenium 55 aminotransferase levels 55 polyposis 55 cTnT 55 antitrypsin 55 underwent coronary angiography 55 advanced adenomas 55 TURP 55 external beam radiotherapy 55 D dimer 55 Multivariate analysis revealed 55 androgen deficiency 55 renal pelvis 55 highest tertile 55 comorbid illnesses 55 varicocele 55 normal karyotype 55 sonographic appearance 55 troponin T 55 biochemical abnormalities 55 Atypical antipsychotics 55 lipid abnormalities 55 interquartile range 55 Pharmacokinetics PK 55 IM progesterone 55 fructose intolerance 55 conventional coronary angiography 55 F FDG PET 55 ELBW infants 55 serum parathyroid hormone 55 aged ≥ 55 nondiabetic 55 SGAs 55 FEV ^ sub 55 chi ^ sup 55 chi squared 55 myeloproliferative diseases 55 HLA A2 55 cryptogenic 55 epithelial tumors 55 pentoxifylline 55 anthropometric measurements 55 gonococcal 55 hyperhomocysteinemia 55 docetaxel pretreated 55 ejection fractions 55 tHcy 55 HRQOL 55 Kaplan Meier curves 55 mammographic breast density 55 GH deficient 55 pharmacologic intervention 55 multivariate analysis 55 gadolinium enhanced 55 scintigraphic 55 clinically evaluable 55 β = 55 diastolic pressures 55 airway hyperresponsiveness 55 nonfasting triglyceride levels 55 patientswith 55 CLBP 55 NATRECOR ® 55 adrenal function 55 arteriography 55 dosimetric 55 breast carcinoma 55 peri procedural 55 bacillus Calmette Guerin 55 arterial oxygen saturation 55 Venous thromboembolism 55 microvessel density 55 myocardial dysfunction 55 ERalpha 55 HbA 1c 55 bi ventricular pacing 55 visceral metastases 55 typical antipsychotics 55 CSF biomarkers 55 Visual Analogue Scale VAS 55 GISTs 55 incomplete revascularization 55 hyperlipidaemia 55 extrapyramidal symptoms 55 elevated creatinine 55 stratifying patients 55 treat NNT 55 echocardiographic parameters 55 Histopathological 55 urography 55 deletion 5q 55 inotropic agents 55 LVEF 55 anticonvulsant medications 55 bioavailable testosterone 55 multivariate logistic regression 55 preterm neonates 55 nonadherence 55 duplex ultrasonography 55 pulmonary angiography 55 varices 55 grade squamous intraepithelial 55 MMSE scores 55 atypical neuroleptics 55 renal scarring 55 Cardiotoxicity 55 Preoperatively 55 underlying pathophysiology 55 BRCA1 mutation carriers 55 paricalcitol 55 ventricular dysfunction 55 liver resection 55 PaO 2 55 antimicrobial prophylaxis 55 carotid bruit 55 fluticasone propionate FP 55 tolterodine ER 55 Kruskal Wallis test 55 contrast echocardiography 55 esophageal gastric 55 pulmonary resection 55 CANCIDAS 55 invasive carcinoma 55 FeNO 55 subsyndromal 55 odds ratios ORs 55 femoral neck fractures 55 antiarrhythmic medications 55 urethral stricture 55 postoperative atrial fibrillation 55 mIU L 55 grade cervical intraepithelial 55 serous ovarian cancer 55 nonoperative treatment 55 neurologic outcomes 55 valve implantation 55 drug eluting stent implantation 55 metabolizer 55 symptomatic fibroids 55 thienopyridines 55 carcinoids 55 titers 55 eplerenone 55 postoperative infections 55 Breslow thickness 55 adjunctively 55 % CI #.#-#.# [005] 55 chemoradiation therapy 55 prognostically 55 serum lactate 55 detrusor overactivity 54 subscale scores 54 Comorbidity 54 thromboembolism 54 oral anticoagulation 54 oral prednisolone 54 multicentric 54 VKORC1 54 hepatic cirrhosis 54 hamartomas 54 statistically significant p = 54 inflammatory biomarkers 54 invasive carcinomas 54 hip BMD 54 G6PD deficiency 54 hypothalamic amenorrhea 54 nodal metastasis 54 QRS duration 54 debulking surgery 54 endometrial carcinoma 54 IL#B 54 rhGH 54 everolimus eluting stents 54 proctitis 54 dysfunction LVSD 54 silent myocardial ischemia 54 Brief Psychiatric 54 undetectable HBV DNA 54 microscopic hematuria 54 % CI #.#-#.# [004] 54 liver transplant recipients 54 intestinal permeability 54 substudy 54 hormone receptor status 54 serum testosterone 54 DES implantation 54 conventional angiography 54 bicuspid aortic valves 54 serum homocysteine 54 paraneoplastic 54 hypothalamic pituitary 54 efficacy evaluable 54 diffusion tensor 54 hepatic metastases 54 hypomagnesemia 54 comorbid psychiatric 54 lupus anticoagulant 54 pg ml 54 polyp recurrence 54 hemodynamically significant 54 completely resected 54 chest radiograph 54 tipranavir ritonavir 54 authors hypothesized 54 pharmacologic therapy 54 immunohistochemical analysis 54 HER2 positive cancers 54 overactive bladder symptoms 54 functional gastrointestinal disorders 54 cerebral microbleeds 54 vascularisation 54 valvular 54 comorbid 54 antithrombotic therapy 54 Afib 54 perinatal outcomes 54 cystoscopic 54 hsCRP 54 adjuvant radiotherapy 54 overt nephropathy 54 CP CPPS 54 cerebral oxygenation 54 irbesartan 54 serum bicarbonate 54 pharmacodynamics PD 54 histopathologic findings 54 platelet inhibitor 54 metabolite concentrations 54 posttest 54 mild renal insufficiency 54 HIV seropositive 54 HLA DRB1 * 54 sonographic findings 54 hyperintensities 54 Comorbidities 54 cervicitis 54 infarcts 54 HbF 54 paroxetine sertraline 54 biochemical relapse 54 somatoform disorders 54 aldosterone antagonists 54 loop diuretic 54 revascularizations 54 Leydig cell 54 chlorthalidone 54 reinfarction 54 coronary angiography 54 hepatic arterial 54 AUCs 54 methacholine 54 K ras mutations 54 operable breast cancer 54 #β estradiol 54 serum thyroglobulin 54 thrombolytic agents 54 UGT#A# * 54 apolipoprotein B 54 pericardial effusion 54 nulliparous women 54 pyridostigmine 54 hydronephrosis 54 Plasma concentrations 54 Prognostic factors 54 intravascular ultrasonography 54 hemodilution 54 perfusion defect 54 Main Outcome Measure 54 nonpregnant women 54 intraobserver 54 HER2 amplification 54 nonmetastatic 54 rFSH 54 serum PTH 54 deep venous thromboses 54 histopathologic 54 DHCA 54 strontium ranelate 54 URTI 54 multivessel disease 54 leukocyte counts 54 myocardial viability 54 thrombolytic therapy 54 diagnostic modality 54 neurocognitive deficits 54 endocrine therapies 54 erythropoietic 54 astrocytomas 54 ß = 54 surgical debulking 54 triacylglycerol concentrations 54 Complication rates 54 generalisable 54 syndromal 54 hepatocellular carcinomas 54 cytogenic 54 pairwise comparisons 54 LDL HDL 54 eNO 54 polycythemia vera essential thrombocythemia 54 bacterial prostatitis 54 immunostaining 54 hyperplastic polyps 54 serum ferritin 54 Charlson Comorbidity Index 54 esophagogastroduodenoscopy 54 concomitant AEDs 54 preoperative 54 upper gastrointestinal bleeding 54 etiologic factors 54 colorectal neoplasia 54 microalbuminuria 54 CLINICAL PHARMACOLOGY 54 Rating Scale BPRS 54 aromatase inhibitors AIs 54 dalteparin 54 dyspareunia 54 ALT flares 54 idiopathic pulmonary arterial hypertension 54 coronary revascularization 54 Prognostic significance 54 sternal wound infections 54 viral kinetics 54 nonoperative 54 HBsAg 54 CYP#C# gene 54 lamivudine refractory patients 54 somatic symptoms 54 cervical intraepithelial neoplasia 54 affective psychoses 54 estrogen receptor ER 54 anti Xa 54 distal radial fractures 54 recurrent UTI 54 thyroid dysfunction 54 baroreceptor 54 â ‰ ¥ 54 SUVmax 54 lymphovascular invasion 54 intravenous cyclophosphamide 54 coronary microvascular 54 dyspnoea 54 ug dose 54 lobular carcinomas 54 neurodevelopmental outcomes 54 underwent resection 54 GOUT 54 AOR = 54 bronchopulmonary dysplasia BPD 54 hypotensive 54 RARP 54 immunomodulatory therapy 54 covariate 54 coronary calcification 54 Secondary endpoints included 54 Primary endpoints 54 serum BDNF 54 intracranial hemorrhage ICH 54 left ventricular dysfunction 54 esophageal carcinoma 54 carotid endarterectomy CEA 54 UA NSTEMI 54 immunomodulation 54 #mg QD [002] 54 systolic BP 54 Exacerbations 54 neovascular glaucoma 54 antidiabetic drugs 54 HIV coinfected 54 interferon ribavirin 54 serum antibody 54 trimethoprim sulfamethoxazole 54 jugular venous 54 ADAS cog 54 immunocompetent 54 NHANES III 54 sirolimus eluting stents 54 neoadjuvant chemotherapy 54 retrograde ejaculation 54 isoproterenol 54 ovariectomized rats 54 TNF antagonist 54 serum testosterone levels 54 rFVIIa 54 euthymic patients 54 urinary incontinence UI 54 ischemic lesions 54 nomograms 54 bronchial responsiveness 54 prucalopride 54 multivariate adjusted 54 lipid profiles 54 triglyceride concentrations 54 plasma homocysteine 54 adjunctive placebo 54 CYP#D# genotype 54 C. trachomatis 54 waist circumference WC 54 prospective multicenter study 54 serologic testing 54 serum markers 54 fasting triglyceride levels 54 generalized estimating 54 NPH insulin 54 unfractionated heparin 54 neutrophil counts 54 atypical antipsychotic medications 54 tumor necrosis 54 PSQI 54 vivo potency 54 RAS mutations 54 colonic polyps 54 anemia hemoglobin 54 pathologic diagnosis 54 antithrombotic agents 54 Adjuvant chemotherapy 54 microbleeds 54 hyperintensity 54 hemorrhagic complications 54 nonpsychotic 54 revascularisation 54 conventional DMARDs 54 inhaled budesonide 54 nonparametric 54 acute myeloid 54 hepatic fibrosis 54 Exclusion criteria 54 metastatic lymph nodes